Hemab Therapeutics Holdings, Inc.
BioSniper AI · COAG
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead programs including sutacimig for Glanzmann thrombasthenia (Breakthrough Therapy Designation) and HMB-002 for von Willebrand disease (VWD).
Key risk: Clinical-stage pipeline
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 5 of 6 signals
Tracking 2 pipeline candidates for Hemab Therapeutics Holdings, Inc. · Updated within the last hour.
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead programs including sutacimig for Glanzmann thrombasthenia (Breakthrough Therapy Designation) and HMB-002 for von Willebrand disease (VWD).
- Completed initial public offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq under ticker COAG [news · 2026-05-21]
- Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia [news · 2026-05-21]
- HMB-002 is a human Fc-silenced monovalent IgG4 antibody designed to elevate endogenous VWF and FVIII levels for subcutaneous prophylaxis in VWD [pubmed · 2026-04-14]
- IPO priced at $18.00 per share, upsized to 19,262,500 shares including full exercise of underwriters' option [news · 2026-05-04]
- Preclinical data show HMB-002 extends VWF half-life and sustains elevated VWF and FVIII levels in cynomolgus monkeys [pubmed · 2026-04-14]
What works
- Breakthrough Therapy Designation for sutacimig may accelerate regulatory review and development [news · 2026-05-21]
- HMB-002 has potential for convenient subcutaneous prophylaxis, addressing limitations of current VWD therapies that require frequent IV administration [pubmed · 2026-04-14]
- IPO raised substantial capital ($346.7M gross) to fund pipeline advancement [news · 2026-05-21]
What to weigh
- Company is clinical-stage with no approved products; all programs face clinical and regulatory risks [news · 2026-05-03]
- HMB-002 is still in preclinical development (animal studies), with human trials yet to demonstrate safety and efficacy [pubmed · 2026-04-14]
- Coagulation disorder market is competitive, with established factor replacement therapies and gene therapies
From the filings
Quoted directly from source documents.
HMB-002 mechanism and design
“HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease.”
PubMed · April 14, 2026
Breakthrough Therapy Designation for sutacimig
“Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia”
News · May 21, 2026
IPO gross proceeds
“completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq”
News · May 21, 2026
IPO pricing and size
“pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of $18.00 per share.”
News · April 30, 2026
Risks & what to watch (4)›
Key risks
- Clinical-stage pipeline — No approved products; sutacimig and HMB-002 are in clinical/preclinical stages with inherent failure risk [news · 2026-05-03]
- Early-stage HMB-002 program — HMB-002 is still in preclinical animal studies; human efficacy and safety are unproven [pubmed · 2026-04-14]
- Competition in hemostasis — Established and emerging therapies for VWD and Glanzmann thrombasthenia may limit market adoption if approved
- Dependence on IPO proceeds — No revenue; company relies on IPO cash ($346.7M) to fund operations until potential product approvals [news · 2026-05-21]
What to watch
- Initiation of clinical trials for HMB-002 in VWD patients [pubmed · 2026-04-14]
- Regulatory milestones for sutacimig following Breakthrough Therapy Designation [news · 2026-05-21]
- Updates on Glanzmann thrombasthenia program clinical data
- Cash runway and spending rate as a clinical-stage company post-IPO
Sources: News · PubMed · Generated July 14, 2026 · How we verify sources →
Unlock the full Hemab Therapeutics Holdings, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Hemab Therapeutics Holdings, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.2 months
OCF -$22M · Net income -$23M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
16 buys · 0 sells (180d)
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Hemab Therapeutics Holdings, Inc.?
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead programs including sutacimig for Glanzmann thrombasthenia (Breakthrough Therapy Designation) and HMB-002 for von Willebrand disease (VWD).
What is Hemab Therapeutics Holdings, Inc.'s lead drug candidate?
Hemab Therapeutics Holdings, Inc.'s most advanced tracked candidate is hmb-002 (Clinical).
Who is the CEO of Hemab Therapeutics Holdings, Inc.?
Dr. Benny Sorensen M.D., Ph.D. is the chief executive officer of Hemab Therapeutics Holdings, Inc. (COAG).
Where is Hemab Therapeutics Holdings, Inc. headquartered?
Hemab Therapeutics Holdings, Inc. (COAG) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Hemab Therapeutics Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.